Skip to main content
SpringerLink
Log in

Leukocyte Depleted Blood Transfusion in Hematopoietic Stem Cell Reconstitution Therapy

  • Chapter
Clinical Benefits of Leukodepleted Blood Products

Part of the book series: Medical Intelligence Unit ((MIUN))

  • 75 Accesses

Summary

The transfusion of red blood cells and platelets is an essential element in the treatment of patients undergoing hematopoietic stem cell transplantation. While blood component therapy has enabled patients to survive the cytopenic period of stem cell therapy, it has been accompanied by the risks and discomforts of transfusion. Although it has been known for almost 30 years that leukocyte depletion is an effective means of preventing many febrile reactions to red blood cell transfusions, only in the last few years has it become apparent that the present technical capability for leukocyte depletion of red blood cell and platelet concentrates affords the opportunity potentially to prevent alloimmunization to HLA antigens and also reduce cytomegalovirus (CMV) transmission as effectively as CMV-seronegative components. Additionally, it is possible that leukocyte depleted components do not cause the immunosuppressive effects noted after allogeneic blood transfusion. Further, there is evidence that there is no clinical disadvantage to providing leukocyte depleted red blood cells and platelets.

There is strong circumstantial evidence that the use of leukocyte depleted red blood cell and platelet components from the time of diagnosis in individuals who may undergo stem cell transplantation and their continued use during transplant therapy is a cost effective strategy for improving patient care.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 39.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 54.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Freedman JJ, Blajchman MA, McCombie N. Canadian Red Cross Society Symposium on Leukodepletion: report of proceedings. Transf Med Rev 8: 1, 1994.

    Article  CAS  Google Scholar 

  2. Lane TA, Anderson KC, Goodnough LT, et al. Leukocyte reduction in blood component therapy. Ann Int Med 117: 151, 1992.

    Article  PubMed  CAS  Google Scholar 

  3. Doan CA. The recognition of a biologic differentiation in the white blood cell with especial reference to blood transfusion. JAMA 86: 1593, 1926.

    Article  Google Scholar 

  4. Brittingham TC, Chaplin H Jr. Febrile transfusion reactions caused by sensitivity to donor leukocytes and platelets. JAMA 165: 819, 1957.

    Article  CAS  Google Scholar 

  5. Perkins HA, Payne R, Ferguson J, Wood M. Nonhemolytic febrile transfusion reactions. Quantitative effects of blood components with emphasis on isoantigenic incompatibility of leukocytes. Vox Sang 11: 578, 1966.

    Article  PubMed  CAS  Google Scholar 

  6. Menitove JE, McElligott MC, Aster RH. Febrile transfusion reaction: what component should be given next? Vox Sang 42: 318, 1982.

    Article  PubMed  CAS  Google Scholar 

  7. Walker RH, ed. Technical Manual. 11th ed. Bethesda, MD. American Association of Blood Banks, 1993.

    Google Scholar 

  8. Mintz PD. Febrile reactions to platelet transfusions. Am J Clin Pathol 95: 609, 1991.

    PubMed  CAS  Google Scholar 

  9. Decary F, Ferner P, Giavedoni L, et al. An investigation of non-hemolytic transfusion reactions. Vox Sang 46: 277, 1984.

    Article  PubMed  CAS  Google Scholar 

  10. de Rie MA, van der Plas-van Dalen CM, Engelfriet CP, von dem Borne AEGK: The serology of febrile transfusion reactions. Vox Sang 49: 126, 1985.

    Article  Google Scholar 

  11. Brubaker DB. Clinical significance of white cell antibodies in febrile nonhemolytic transfusion reactions. Transfusion 30: 733, 1990.

    Article  PubMed  CAS  Google Scholar 

  12. Dinarello CA, Wolff SM. Molecular basis of fever in humans. Am J Med 72: 799, 1982.

    Article  PubMed  CAS  Google Scholar 

  13. Dzik WH. Is the febrile response to transfusion due to donor or recipient cytokine? Transfusion 32: 594, 1992.

    Article  PubMed  CAS  Google Scholar 

  14. Okusawa S, Dianrello CA, Endres S, et al.: C5a induction of human interleukin-1: synergistic effect with endotoxin or interferon“. J Immunol 139: 2635, 1987.

    PubMed  CAS  Google Scholar 

  15. Muylle L, Joos M, Wouters E, De Bock R, Peetermans ME. Increased tumor necrosis factor a (TNFa), interleukin 1, and interleukin 6 (IL-6) levels in the plasma of stored platelet concentrates: relationship between TNFa and IL-6 levels and febrile transfusion reactions. Transfusion 33: 195, 1993.

    Article  PubMed  CAS  Google Scholar 

  16. See Aye as referenced in Freedman JJ, Blajchman MA, McCombie N. Canadian Red Cross Society Symposium on Leukodepletion: Report of Proceedings. Transf Med Rev 8: 1, 1994.

    Google Scholar 

  17. Stack G, Snyder EL. Cytokine generation in stored platelet concentrates. Transfusion 34: 20, 1994.

    Article  PubMed  CAS  Google Scholar 

  18. Smith KJ, Sierra ER, Nelson EJ. Plasma 1L-8 and 1L-6 increase in platelet concentrates (PC) stored for 5 days but not in PC leukodepleted pre-storage. Transfusion 33: 53S, 1993.

    Google Scholar 

  19. Smith KJ, Sierra ER, Nelson EJ. Histamine, IL-1B, and IL-8 increase in packed RBCs stored for 42 days but not in RBCs leukodepleted pre-storage. Transfusion 33: 53S, 1993.

    Google Scholar 

  20. Meryman HT, Hornblower M. The preparation of red cells depleted of leukocytes: review and evaluation. Transfusion 26: 101, 1986.

    Article  PubMed  CAS  Google Scholar 

  21. Sirchia G, Rebulla P, Parravicini A, Carnelli V, Gianotti AG, Bertolini F. Leukocyte depletion of red cell units at the bedside by transfusion through a new filter. Transfusion 27: 402, 1987.

    Article  PubMed  CAS  Google Scholar 

  22. Sirchia G, Wenz B, Rebulla P, Parravicini A, Carnelli V, Bertolini, F. Removal of white cells from red cells by transfusion through a new filter. Transfusion 30: 30, 1990.

    Article  PubMed  CAS  Google Scholar 

  23. Dan ME, Stewart S. Prevention of recurrent febrile transfusion reactions using leukocyte poor platelet concentrates prepared by the “leukotrap” centrifugation method. Transfusion 26: 569, 1986.

    Google Scholar 

  24. Stec N, Kickler TS, Ness PM, Braine HG. Effectiveness of leukocyte (WBC) depleted platelets in preventing febrile reactions in multi-transfused oncology patients. Transfusion 26: 569, 1986.

    Article  Google Scholar 

  25. Schiffer CA, Patten E, Reilly J, Patel S. Effective leukocyte removal from platelet preparations by centrifugation in a new pooling bag. Transfusion 27: 162, 1987.

    Article  PubMed  CAS  Google Scholar 

  26. Kalmin ND, Orell JE, Villarreal IG. An effective method for the preparation of leukocyte-poor platelets. Transfusion 27: 281, 1987.

    Article  PubMed  CAS  Google Scholar 

  27. Sternbach M, Champagne J, Rybka W, Paquin M. Leukotrap, a device for white cell poor platelets. Quality control studies in vitro and in vivo. Trans Science 10: 57, 1989.

    Article  Google Scholar 

  28. Slichter SJ. Mechanisms and management of platelet refractoriness. In: Nance SJ, ed. Transfusion Medicine in the 1990s. Arlington, VA. American Association of Blood Banks, 95, 1990.

    Google Scholar 

  29. Mangano MM, Chambers LA, Kruskall MS. Limited efficacy of leukopoor platelets for prevention of febrile transfusion reactions. Am J Clin Pathol. 95: 733, 1991.

    PubMed  CAS  Google Scholar 

  30. Goodnough LT, Riddell J, Lazarus H, Chafel TL, Prince G, Hendrix D, Yomtovian R. Prevalence of platelet transfusion reactions before and after implementation of leukocyte-depleted platelet concentrates by filtration. Vox Sang 65: 103, 1993.

    Article  PubMed  CAS  Google Scholar 

  31. Confer DL. The prevention of HLA alloimmunization. In: Clinical Decisions in Platelet Therapy 1992.

    Google Scholar 

  32. Rio B, Nichol AG, et al. Thrombocytopenia in venoocclusive disease after bone marrow transplantation or chemotherapy. Blood 67: 1773, 1986.

    PubMed  CAS  Google Scholar 

  33. Lee EJ, Schiffer CA. Serial measurement of lymphocytotoxic antibody and response to non-matched platelet transfusions in alloimmunization patients. Blood 70: 1727, 1987.

    PubMed  CAS  Google Scholar 

  34. Schiffer CA, Lichtenfeld JL, Wiernik PH, Mardiney MR, Joseph JM. Antibody response in patients with acute non-lymphocytic leukemia. Cancer 37: 2177, 1976.

    Article  PubMed  CAS  Google Scholar 

  35. Dutcher JP, Schiffer CA, Aisner J, Wiernik PH. Long-term follow-up of patients with leukemia receiving platelet transfusions: Identification of a large group of patients who do not become alloimmunized. Blood 58: 1007, 1981.

    PubMed  CAS  Google Scholar 

  36. Daly PA, Schiffer CA, Aisner J, Wiernik PA. Platelet transfusion therapy-One hour post-transfusion increments are valuable in predicting the need for HLA-matched preparations. JAMA 243: 435, 1980.

    Article  PubMed  CAS  Google Scholar 

  37. O’Connell B, Lee EJ, Schiffer CA. The value of 10-minute posttransfusion platelet counts. Transfusion 28: 66, 1988.

    Article  PubMed  Google Scholar 

  38. Bishop JF, McGrath K, Wolf MM, et al. Clinical factors influencing the efficacy of pooled platelet transfusions. Blood 71: 383, 1988.

    PubMed  CAS  Google Scholar 

  39. Kickler TS. The challenge of platelet alloimmunization: management and prevention. Trans Med Rev 4: 8, 1990.

    Article  CAS  Google Scholar 

  40. Kickler T, Braine HG, Piantodosi S, et al. A randomized, placebo-controlled trial of intravenous gammaglobulin in alloimmunized thrombocytopenic patients. Blood 75: 313, 1990.

    PubMed  CAS  Google Scholar 

  41. Sintnicolaas K, Sizoo W, Haije WG, et al. Delayed alloimmunisation by random single donor platelet transfusions. A randomised study to compare single donor and multiple donor platelet transfusions in cancer patients with severe thrombocytopenia. Lancet 1: 750, 1981.

    Article  PubMed  CAS  Google Scholar 

  42. Gmür J, von Felten A, Osterwalder B, et al. Delayed alloimmunization using random single donor platelet transfusions: A prospective study in thrombocytopenic patients with acute leukemia. Blood 62: 473, 1983.

    PubMed  Google Scholar 

  43. Heddle NM. The efficacy of leukodepletion to improve platelet transfusion response: a critical appraisal of clinical studies. Trans Med Rev. 8: 15, 1994.

    Article  CAS  Google Scholar 

  44. Andreu G, Boccaccio C, Klaren J, et al. The role of UV radiation in the prevention of human leukocyte antigen alloimmunization. Trans Med Rev 6: 212, 1992.

    Article  CAS  Google Scholar 

  45. Eernisse JG, Brand A. Prevention of platelet refractoriness due to HLA antibodies by administration of leukocyte-poor blood components. Exp Hematol 9: 77, 1981.

    PubMed  CAS  Google Scholar 

  46. Schiffer CA, Dutcher JP, Aisner J, et al. A randomized trial of leukocyte-depleted platelet transfusion to modify alloimmunization in patients with leukemia. Blood 62: 815, 1983.

    PubMed  CAS  Google Scholar 

  47. Fisher M, Chapman JR, Ting A, Morris PJ. Alloimmunisation to HLA antigens following transfusion with leucocyte-poor and purified platelet suspensions. Vox Sang 49: 331, 1985.

    Article  PubMed  CAS  Google Scholar 

  48. Murphy ME, Metcalfe P, Thomas H, et al. Use of leucocyte-poor blood components and HLA-matched-platelet donors to prevent HLA alloimmunization. Br J Haematol 62: 529, 1986.

    Article  PubMed  CAS  Google Scholar 

  49. Sniecinski I, O’Donnell MR, Nowicki B, et al. Prevention of refractoriness and HLAalloimmunization using filtered blood products. Blood 71: 1402, 1988.

    PubMed  CAS  Google Scholar 

  50. Andreu G, Dewailly J, Leberre C, et al. Prevention of HLA immunization with leukocyte-poor packed red cells and platelet concentrates obtained by filtration. Blood 72: 964, 1988.

    PubMed  CAS  Google Scholar 

  51. Brand A, Claas FHJ, Voogt PJ, et al. Alloimmunization after leukocyte-depleted multiple random donor platelet transfusions. Vox Sang 54: 160, 1988.

    Article  PubMed  CAS  Google Scholar 

  52. Saarinen UM, Kekomäki R, Siimes MA, et al. Effective prophylaxis against platelet refractoriness in multitransfused patients by use of leukocyte-free blood components. Blood 75: 512, 1990.

    PubMed  CAS  Google Scholar 

  53. Oksanen K, Kekomäki R, Ruutu T, et al. Prevention of alloimmunization in patients with acute leukemia by use of white cell-reduced blood components-A randomized trial. Transfusion 31: 588, 1991.

    Article  PubMed  CAS  Google Scholar 

  54. van Marwijk Kooy M, van Prooijen HC, Moes M, et al. Use of leukocyte-depleted platelet concentrates for the prevention of refractoriness and primary HLA allo-immunization: A prospective, randomized trial. Blood 77: 201, 1991.

    Google Scholar 

  55. Saarinen UM, Koskimies S, Myllylä G. Systematic use of leukocyte-free blood components to prevent alloimmunization and platelet refractoriness in multitransfused children with cancer. Vox Sang 65: 286, 1993.

    Article  PubMed  CAS  Google Scholar 

  56. Slichter SJ, O’Donnell MR, Weiden PL, et al. Canine platelet alloimmunization: the role of donor selection. Br J Hematol 63: 713, 1986.

    Article  CAS  Google Scholar 

  57. Welsh KI, Burgos H, Batchelor JR. The immune response to allogeneic rat platelets: Ag-B antigens in matrix form lacking la. Eur J Immunol 7: 267, 1977.

    Article  PubMed  CAS  Google Scholar 

  58. Dausset J, Rapaport FT. Transplantation antigen activity of human blood platelets. Transplantation 4: 182, 1966.

    Article  PubMed  CAS  Google Scholar 

  59. Buchholz DH, Miripol J, Aster RH, et al. Ultraviolet irradiation of platelets to prevent recipient alloimmunization. Transfusion 28: S91, 1988.

    Google Scholar 

  60. Menitove JE, Kagen LR, Aster RH, et al. Alloimmunization is decreased in patients receiving UV-B irradiated platelet concentrates and leukocyte-depleted red cells. Blood 76: 1607, 1990.

    Google Scholar 

  61. Pamphilon DH, Blundell EL. Ultraviolet B irradiation of platelet transfusions: A strategy to reduce recipient alloimmunization. Semin Hematol 29: 118, 1992.

    Google Scholar 

  62. Kahn RA, Duffy BF, Rodey GG. Ultraviolet irradiation of platelet concentrate abrogates lymphocyte activation without affecting platelet function in vitro. Transfusion 25: 547, 1985.

    Article  PubMed  CAS  Google Scholar 

  63. Snyder EL, Beardsly D, Smith B, et al. Storage of platelet concentrates after UV-B irradiation. Blood 74: 179a (abstr), 1989.

    Google Scholar 

  64. Pamphilon DH, Potter M, Cutts M, et al. Platelet concentrates irradiated with ultraviolet light retain satisfactory in vitro storage characteristics and in vivo survival. Br J Haematol 75: 240, 1990.

    Article  PubMed  CAS  Google Scholar 

  65. Blajchman MA, Bardossy L, Carmen RA, Goldman M, Heddle NM, Singal DP. An animal model of allogeneic donor platelet refractoriness: the effect of the time of leukodepletion. Blood 79: 1371, 1992.

    PubMed  CAS  Google Scholar 

  66. Schiffer CA. Prevention of alloimmunization against platelets. Blood 77: 1, 1991.

    PubMed  CAS  Google Scholar 

  67. Perkins HA. Is white cell reduction effective? Transfusion 33: 626, 1993.

    Article  PubMed  CAS  Google Scholar 

  68. Balducci L, Benson K, Lyman GH, Sanderson R, Fields K, Ballester OF, Elfenbein GJ. Cost-effectiveness of white cell-reduction filters in treatment of adult acute myelogenous leukemia. Transfusion 33: 665, 1993.

    Article  PubMed  CAS  Google Scholar 

  69. Blumberg N, Heal J, Kirkley S, Panzer R, Rowe J. Cost effectiveness of leukodepleted (LD) transfusions during induction therapy for acute leukemia. Transfusion 33: 84S, 1993.

    Google Scholar 

  70. Sniecinski I. Prevention of immunologic and infectious complications of transfusion by leukocyte depletion. In: Clinical Application of Leukocyte Depletion. Sekiguchi S, ed, Blackwell Scientific Publication, Osney Mead Oxford, 1993.

    Google Scholar 

  71. Blumberg N, Heal J, Rapoport A, DiPersio J, Rowe J, Panzer R. Effect of ABO-identical platelets and leukodepletion (LD) on blood utilization and costs of autologous marrow transplantation (BMT). Transfusion 33: 83S, 1993.

    Google Scholar 

  72. Oksanen K, Elonen E. Impact of leucocyte-depleted blood components on the haematological recovery and prognosis of patients with acute myeloid leukaemia. Br J Haem 84: 639, 1993.

    Article  CAS  Google Scholar 

  73. Hirsch MS. Ctyomegalovirus infection. In: Harrison’s Principles of Internal Medicine. 12th ed. Wilson JD, et al, eds., McGraw-Hill, Inc. 1991.

    Google Scholar 

  74. Kaariainen L, Klemola E, Paloheimo J. Rise of cytomegalovirus antibodies in an infectious mononucleosis-like syndrome after transfusion. Br Med J 1: 1270, 1966.

    Article  PubMed  CAS  Google Scholar 

  75. Sayers MH, Anderson KC, Goodnough LT. Reducing the risk for transfusion-transmitted cytomegalovirus infection. Ann Int Med 116: 55, 1992.

    Article  PubMed  CAS  Google Scholar 

  76. Verdonck LF, van Heugten H, de Gast GC. Delay in platelet recovery after bone marrow transplantation: impact of cytomegalovirus infection. Blood 66: 921, 1985.

    PubMed  CAS  Google Scholar 

  77. Wingard JR, Ghen DY, Burns WH, Fuller DJ, Braine HG, Yeager AM, et al. Cytomegalovirus infection after autolgous bone marrow transplantation with comparison to infection after allogeneic bone marrow transplantation. Blood 71: 1432, 1988.

    PubMed  CAS  Google Scholar 

  78. Reusser P, Fisher LD, Buckner CD, Thomas ED, Meyers JD. Cytomegalovirus infection after autologous bone marrow transplantation: occurrence of cytomegalovirus disease and effect on engraftment. Blood 75: 1888, 1990.

    PubMed  CAS  Google Scholar 

  79. Bowden RA, Sayers M, Flournoy N, Newton B, Banaji M, Thomas ED, et al. Cytomegalovirus immune globulin and seronegative blood products to prevent primary cytomegalovirus infection after marrow transplantation. N Engl J Med 314: 1006, 1986.

    Article  PubMed  CAS  Google Scholar 

  80. Lang DJ, Ebert PA, Rodgers BM, Boggess HP, Rixse RS. Reduction of postperfusion cytomegalovirus infections following the use of leukocyte depleted blood. Transfusion 17: 391, 1977.

    Article  PubMed  CAS  Google Scholar 

  81. Luban NL, Williams AE, McDonald MG, Mikesell GT, Williams KM, Sacher RA. Low incidence of cytomegalovirus infection in neonates transfused with washed red blood cells. Am J Dis Child 141: 416, 1987.

    PubMed  CAS  Google Scholar 

  82. Tolkoff-Rubin NA, Rubin RH, Keller EE, Baker GP, Stewart JA, Hirsch MS. Cytomegalovirus infection in dialysis patients and personnel. Ann Intern Med 89: 625, 1978.

    Article  PubMed  CAS  Google Scholar 

  83. Betts RF, Cestero RV, Freeman RB, Douglas RG Jr. Epidemiology of cytomegalovirus infection in end stage renal disease. J Med Virol 4: 89, 1979.

    Article  PubMed  CAS  Google Scholar 

  84. Adler SP, Lawrence LT, Baggett J, Biro V, Sharp DE. Prevention of transfusion-associated cytomegalovirus infection in very lowbirth-weight infants using frozen blood and donors seronegative for cytomegalovirus. Transfusion 24: 333, 1984.

    Article  PubMed  CAS  Google Scholar 

  85. Brady MT, Milam JD, Anderson DC, Hawkins EP, Speer ME, Seavy D, et al. Use of deglycerolized red blood cells to prevent posttransfusion infection with cytomegalovirus in neonates. J Infect Dis 150: 334, 1984.

    Article  PubMed  CAS  Google Scholar 

  86. Taylor BJ, Jacobs RF, Baker RL, Moses EB, McSwain BE, Shulman G. Frozen deglycerolyzed blood prevents transfusion-acquired cytomegalovirus infections in neonates. Pediatr Infect Dis 5: 188, 1986.

    Article  PubMed  CAS  Google Scholar 

  87. Verdonck LF, de Graan-Hentzen YC, Dekker AW, Mudde GC, de Gast GC. Cytomegalovirus seronegative platelets and leukocyte-poor red blood cells from random donors can prevent primary cytomegalovirus infection after bone marrow transplantation. Bone Marrow Transplant 2: 73, 1987.

    PubMed  CAS  Google Scholar 

  88. Murphy MF, Grint PC, Hardiman AE, Listet TA, Waters AH. Use of leukocyte-poor blood components to prevent primary cytomegalovirus (CMV) infection in patients with acute leukemia. Br J Haematol 70: 253, 1988.

    Article  PubMed  CAS  Google Scholar 

  89. Gilbert GL, Hayes K, Hudson IL, James J. Prevention of transfusion-acquired cytomegalovirus infection in infants by blood filtration to remove leucocytes. Neonatal Cytomegalovirus Infection Study Group. Lancet 1: 1228, 1989.

    Article  PubMed  CAS  Google Scholar 

  90. De Graan-Hentzen YCE, Gratama JW, Mudde GC, et al. Prevention of primary cytomegalovirus infection in patients with hematologic malignancies by intensive white cell depletion of blood products. Transfusion 29: 757, 1989.

    Article  PubMed  Google Scholar 

  91. Bowden RA, Sayers MH, Cays M, Slichter SJ. The role of blood product filtration in the prevention of transfusion associated cytomegalovirus (CMV) infection after marrow transplant (Abstract). Transfusion 29: 57S, 1989.

    Google Scholar 

  92. DeWitte T, Schattenberg A, van Dijk BA, Galama J, Olthuis H, Van der Meer JW, Kunst VA. Prevention of primary cytomegalovirus infection after allogeneic bone marrow transplantation by using leukocyte-poor random blood products from cytomegalovirus-unscreened blood-bank donors. Transplantation 50: 964, 1990.

    Article  CAS  Google Scholar 

  93. Bowden RA, Slichter SJ, Sayers MH, Mori M, Cays MJ, Meyers JD. Use of leukocyte-depleted platelets and cytomegalovirusseronegative red blood cells for prevention of primary cytomegalovirus infection after marrow transplant. Blood 78: 246, 1991.

    PubMed  CAS  Google Scholar 

  94. Eisenfield L, Silver H, McLaughlin J, et al. Prevention of transfusion-associated cytomegalovirus infection in neonatal patients by the removal of white cells from blood. Transfusion 32: 205, 1992.

    Article  Google Scholar 

  95. Bowden RA, Cays M, Schoch G, et al. Comparison of filtered blood (FB) to seronegative blood products (SB) for prevention of cytomegalovirus (CMV) infection after marrow transplant. Blood 82: 204a, 1993.

    Google Scholar 

  96. Morrow JF, Braine HG, Kickler TS, et al. Septic reactions to platelet transfusions. A persistent problem. JAMA 266: 555, 1991.

    Article  PubMed  CAS  Google Scholar 

  97. Barrett BB, Andersen JW, Anderson KC. Strategies for the avoidance of bacterial contamination of blood components. Transfusion 33: 228, 1993.

    Article  PubMed  CAS  Google Scholar 

  98. Pietersz RNI, Reesink HW, Pauw W, Dekker WJA, Buisman L. Prevention of Yersinia enterocolitica growth in red-bloodcell concentrates. Lancet 340: 755, 1992.

    Article  PubMed  CAS  Google Scholar 

  99. Högman CF, Gong J, Hambraeus A, Johansson CS, Eriksson L. The role of white cells in the transmission of Yersinia enterocolitica in blood components. Transfusion 32: 654, 1992.

    Article  PubMed  Google Scholar 

  100. Kim DM, Brecher ME, Bland LA, Estes TJ, McAllister SK, Aguero SM, Carmen RA, Nelson EJ. Prestorage removal of Yersinia enterocolitica from red cells with white cell-reduction filters. Transfusion 32: 658, 1992.

    Article  PubMed  CAS  Google Scholar 

  101. Wenz B, Burns ER, Freundlich LF. Prevention of growth of Yersinia enterocolitica in blood by polyester fiber filtration. Transfusion 32: 663, 1992.

    Article  PubMed  CAS  Google Scholar 

  102. Buchholz DH, AuBuchon JP, Snyder EL, et al. Removal of Yersinia enterocolitica from AS-1 red cells. Transfusion 32: 667, 1992.

    Article  PubMed  CAS  Google Scholar 

  103. Nusbacher J. Yersinia enterocolitica and white cell filtration. Transfusion 32: 597, 1992.

    Article  PubMed  CAS  Google Scholar 

  104. Högman CF, Gong J, Eriksson L, Hambraeus A, Johansson CS. White cells protect donor blood against bacterial contamination. Transfusion 31: 620, 1991.

    Article  PubMed  Google Scholar 

  105. See Ali and Blajchman as referenced in Freedman JJ, Blajchman MA, McCombie N. Canadian Red Cross Society Symposium on Leukodepletion: report on proceedings. Transf Med Rev 8: 1, 1994.

    Article  CAS  Google Scholar 

  106. Anderson KC, Weinstein HJ. Transfusion-associated graft-versus-host disease. N Engl J Med 323: 315, 1990.

    Article  PubMed  CAS  Google Scholar 

  107. Deeg HJ, Graham TC, Gerhard-Miller L, et al. Prevention of transfusion-induced graft-versus-host disease in dogs by ultraviolet irradiation. Blood 74: 2592, 1989.

    PubMed  CAS  Google Scholar 

  108. Rubinstein A, Radl J, Cottier H, Rossi E, Gugler E. Unusual combined immunodeficiency syndrome exhibiting kappa-IgD paraproteinemia, residual gut immunity and graft-versus-host reaction after plasma infusion. Acta Paediatr Scand 62: 365, 1973.

    Article  PubMed  CAS  Google Scholar 

  109. Dzik WH, Jones KS. The effects of gamma irradiation versus white cell reduction on the mixed lymphocyte reaction. Transfusion 33: 493, 1993.

    Article  PubMed  CAS  Google Scholar 

  110. Akahoshi M, Takanashi M, Masuda, M, et al. A case of transfusion-associated graftversus-host disease not prevented by white cell-reduction filters. Transfusion 32: 169, 1992.

    Article  PubMed  CAS  Google Scholar 

  111. Klein HG. Transfusion in transplant patients: the good, the bad, and the ugly. J Heart Lung Transplant 12: S7, 1993.

    PubMed  CAS  Google Scholar 

  112. Blajchman MA, Bardossy L, Carmen R, Sastry A, Singai DP. Allogeneic blood transfusion-induced enhancement of tumor growth: two animal models showing amelioration by leukodepletion and passive transfer using spleen cells. Blood 81: 1880, 1993.

    PubMed  CAS  Google Scholar 

  113. Lopez J, Fernandez-Villalta MJ, GomezReino F, Fernandez-Ranada JM. Absence of graft-versus-leukemia effect of standard hemotherapy in patients with acute myeloblastic leukemia. Transfusion 30: 191, 1990.

    Article  PubMed  CAS  Google Scholar 

  114. Norol F, Parquet N, Kuentz M, et al. Absence of graft-versus-leukaemia (GVL) effect by leucocytes transfused: a prospective randomized trial in acute myeloid leukaemia (AML) patients. Br J Haem 78: 591, 1991.

    Article  CAS  Google Scholar 

  115. Rebulla P, Pappalettera M, Barbui T, et al. Duration of first remission in leukaemic recipients of leucocyte-poor blood components. Br J Haem 75: 441, 1990.

    Article  CAS  Google Scholar 

Download references

Authors
  1. John P. Miller
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Paul D. Mintz
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

Copyright information

© 1995 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Miller, J.P., Mintz, P.D. (1995). Leukocyte Depleted Blood Transfusion in Hematopoietic Stem Cell Reconstitution Therapy. In: Clinical Benefits of Leukodepleted Blood Products. Medical Intelligence Unit. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-662-26538-3_13

Download citation

  • DOI: https://doi.org/10.1007/978-3-662-26538-3_13

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-1-57059-122-8

  • Online ISBN: 978-3-662-26538-3

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation